DK0732929T3 - Terapeutisk anvendelse af cis-element-afledere in vivo - Google Patents

Terapeutisk anvendelse af cis-element-afledere in vivo

Info

Publication number
DK0732929T3
DK0732929T3 DK95900450T DK95900450T DK0732929T3 DK 0732929 T3 DK0732929 T3 DK 0732929T3 DK 95900450 T DK95900450 T DK 95900450T DK 95900450 T DK95900450 T DK 95900450T DK 0732929 T3 DK0732929 T3 DK 0732929T3
Authority
DK
Denmark
Prior art keywords
endogenous
decoys
binding
provides
therapeutic use
Prior art date
Application number
DK95900450T
Other languages
Danish (da)
English (en)
Inventor
Victor J Dzau
Gary H Gibbons
Ryuichi Morishita
Original Assignee
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22509818&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0732929(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Brigham & Womens Hospital filed Critical Brigham & Womens Hospital
Application granted granted Critical
Publication of DK0732929T3 publication Critical patent/DK0732929T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3517—Marker; Tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Plant Pathology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK95900450T 1993-10-29 1994-10-28 Terapeutisk anvendelse af cis-element-afledere in vivo DK0732929T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14471793A 1993-10-29 1993-10-29
PCT/US1994/012339 WO1995011687A1 (en) 1993-10-29 1994-10-28 Therapeutic use of cis-element decoys in vivo

Publications (1)

Publication Number Publication Date
DK0732929T3 true DK0732929T3 (da) 2008-09-01

Family

ID=22509818

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95900450T DK0732929T3 (da) 1993-10-29 1994-10-28 Terapeutisk anvendelse af cis-element-afledere in vivo

Country Status (8)

Country Link
US (5) US6774118B1 (de)
EP (3) EP1350514A3 (de)
AT (1) ATE395065T1 (de)
DE (1) DE69435100D1 (de)
DK (1) DK0732929T3 (de)
ES (1) ES2307293T3 (de)
PT (1) PT732929E (de)
WO (1) WO1995011687A1 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1350514A3 (de) * 1993-10-29 2004-07-07 The Brigham And Women's Hospital, Inc. Therapeutische Verwendung von Cis-Element Ködern in vivo
US6399376B1 (en) * 1993-11-05 2002-06-04 Isis Pharmaceuticals, Inc. Modulation of vascular cell adhesive molecule expression through oligonucleotide interactions
AU3881095A (en) * 1994-11-17 1996-06-17 Taiho Pharmaceutical Co., Ltd. Double-stranded oligonucleotide and carcinostatic agent containing the same as active ingredient
ATE357922T1 (de) 1995-05-12 2007-04-15 Anges Mg Inc Heilung und vorbeugung von durch nf-kappab verursachten erkrankungen
US6946246B1 (en) 1997-04-08 2005-09-20 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Production of functional proteins: balance of shear stress and gravity
AU5329599A (en) * 1998-07-30 2000-02-21 University Of South Florida Method for the modulation of function of transcription factors
US6599741B1 (en) 1999-09-14 2003-07-29 Avontec Gmbh Modulating transcription of genes in vascular cells
EP1313868B1 (de) * 2000-08-30 2006-07-19 North Carolina State University Transgene pflanzen, die molekulare decoys enthalten, die den proteininhalt ändern
AU2002248185A1 (en) * 2000-12-14 2002-07-16 Coley Pharmaceutical Group, Inc. Inhibition of angiogenesis by nucleic acids
DE60225899T2 (de) 2001-02-20 2009-04-09 AnGes MG Inc., Ibaraki-shi TOPISCHE ANWENDUNG EINES NF-kB DECOYS ZUR BEHANDLUNG ATOPISCHER DERMATITIS
DE10148828B4 (de) * 2001-10-04 2005-05-19 Avontec Gmbh Modulation der Expression STAT-1-abhängiger Gene
WO2003063911A1 (fr) * 2002-02-01 2003-08-07 Anges Mg, Inc. Compositions pharmaceutiques contenant un leurre et procede d'utilisation
US20030224992A1 (en) * 2002-03-15 2003-12-04 Praecis Pharmaceuticals Inc. Transcription factor modulators and uses thereof
CN1240439C (zh) 2002-03-28 2006-02-08 南京凯基生物科技发展有限公司 肿瘤基因开关药物
US20070014840A1 (en) 2002-04-26 2007-01-18 In-Kyu Lee Circular dumbbell decoy oligodeoxynucleotides (cdodn) containing dna bindings sites of transcription
DE10240417A1 (de) * 2002-09-02 2004-03-11 Avontec Gmbh Decoy-Oligonukleotid-Hemmung der CD40-Expression
DE10242319A1 (de) * 2002-09-12 2004-03-25 Avontec Gmbh Funkionelle Korrektur der-786C/T-Varianz des humanen eNOS-Gens
US20040266712A1 (en) * 2003-04-08 2004-12-30 Mcevoy Leslie M. Selective inhibition of vascular smooth muscle cell proliferation
WO2005035547A2 (en) * 2003-10-06 2005-04-21 Corgentech, Inc. E2f oligonucleotide decoy molecules
US7824857B2 (en) 2003-12-02 2010-11-02 Musc Foundation For Research Development Methods and compositions for diagnosing epithelial cell cancer
US8034619B2 (en) * 2003-12-19 2011-10-11 University Of Cincinnati Polyamides for nucleic acid delivery
WO2005079217A2 (en) * 2003-12-19 2005-09-01 University Of Cincinnati Oligonucleotide decoys and methods of use
US7981616B2 (en) 2004-02-27 2011-07-19 Musc Foundation For Research Development Enhanced detection of RNA using a panel of truncated gene-specific primers for reverse transcription
US7482158B2 (en) * 2004-07-01 2009-01-27 Mathison Brian H Composite polynucleic acid therapeutics
AU2005271960B2 (en) 2004-07-09 2011-12-08 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Identification of markers in lung and breast cancer
WO2006012625A2 (en) * 2004-07-22 2006-02-02 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Stat3 decoy oligonucleotides and uses therefor
WO2006043722A1 (ja) 2004-10-22 2006-04-27 Anges Mg, Inc. キメラ（ダブル）デコイ
US7585848B2 (en) 2005-01-11 2009-09-08 Rush University Medical Center Methods and compositions for treating, inhibiting and reversing disorders of the intervertebral disc
US20060234973A1 (en) * 2005-04-14 2006-10-19 Kevin Fitzgerald Transcription factor RNA interference reagents and methods of use thereof
CA2614295A1 (en) * 2005-06-06 2006-12-14 Anges Mg, Inc. Transcription factor decoy
WO2007071069A1 (en) * 2005-12-22 2007-06-28 Institut De Cardiologie De Montreal Transcription factor decoy oligodeoxynucleotides having multiple cis elements
JPWO2007072909A1 (ja) 2005-12-22 2009-06-04 アンジェスＭｇ株式会社 新規オリゴヌクレオチド及びそれから成るＮＦ−κＢデコイ
US8501478B2 (en) * 2006-06-15 2013-08-06 University Of Cincinnati Trehalose click polymers for delivery of biologically active molecules
US20090098529A1 (en) 2006-10-16 2009-04-16 Nanhai Chen Methods for attenuating virus strains for diagnostic and therapeutic uses
JP5384120B2 (ja) 2007-02-16 2014-01-08 アンジェスＭｇ株式会社 歯周病、及び外科手術による歯槽骨欠損の治療剤
PL2158316T3 (pl) 2007-05-11 2015-10-30 Adynxx Inc Ekspresja genowa oraz ból
WO2009117484A2 (en) * 2008-03-18 2009-09-24 University Of South Florida Small molecule e2f inhibitor
KR20100127300A (ko) 2008-03-28 2010-12-03 안게스 엠지 인코포레이티드 전사 인자 디코이를 유효 성분으로 하는 외용제 조성물
WO2011084694A1 (en) 2009-12-17 2011-07-14 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Stabilized stat3 decoy oligonucleotides and uses therefor
EP2846839B1 (de) 2012-05-10 2019-02-20 Adynxx, Inc. Formulierungen zur abgabe von wirkstoffen
WO2014012081A2 (en) 2012-07-13 2014-01-16 Ontorii, Inc. Chiral control
WO2015031628A1 (en) * 2013-08-28 2015-03-05 Oregon Health & Science University Synthetic oligonucleotides for detection of nucleic acid binding proteins
CA2957250A1 (en) 2014-08-15 2016-02-18 Adynxx, Inc. Oligonucleotide decoys for the treatment of pain
JPWO2017068790A1 (ja) * 2015-10-23 2018-08-09 レナセラピューティクス株式会社 核酸複合体
WO2018067165A1 (en) * 2016-10-07 2018-04-12 Miami University Engineered oncolytic viruses containing hyper-binding sites to sequester and suppress activity of oncogenic transcription factors as a novel treatment for human cancer

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804374A (en) * 1980-12-05 1998-09-08 Massachusetts Insti. Technology Nuclear factors associates with transcriptional regulation
US6410516B1 (en) * 1986-01-09 2002-06-25 President & Fellows Of Harvard College Nuclear factors associated with transcriptional regulation
US5264423A (en) 1987-03-25 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5276019A (en) 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
WO1991011535A1 (en) * 1990-01-30 1991-08-08 Childrens Hospital Of Los Angeles Inhibition of transcription by double-stranded oligonucleotides
WO1992018522A1 (en) * 1991-04-18 1992-10-29 The Salk Institute For Biological Studies Oligodeoxynucleotides and oligonucleotides useful as decoys for proteins which selectively bind to defined dna sequences
US6262022B1 (en) * 1992-06-25 2001-07-17 Novartis Ag Pharmaceutical compositions containing cyclosporin as the active agent
US6699985B2 (en) * 1991-08-21 2004-03-02 Arsinur Burcoglu Method of treating HIV infection and related secondary infections thereof
ES2181677T3 (es) * 1991-08-23 2003-03-01 Univ Nebraska Metodo y composiciones utiles en la reprogramacion celular.
WO1993014768A1 (en) * 1992-01-27 1993-08-05 The Trustees Of The University Of Pennsylvania Methods and compositions for neutralizing intracellular nucleic acid-binding protein biological activity in a cell, including methods and compositions useful to regulate gene function
WO1993015227A1 (en) * 1992-01-29 1993-08-05 Duke University Method of assaying for the oncogenic state of cells
US5821234A (en) 1992-09-10 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of proliferation of vascular smooth muscle cell
NZ257181A (en) * 1992-10-29 1997-07-27 Medical Res Council Transcription factor dp-1, dna, vectors and host cells therefor
US5631237A (en) 1992-12-22 1997-05-20 Dzau; Victor J. Method for producing in vivo delivery of therapeutic agents via liposomes
ES2188597T3 (es) * 1993-10-29 2003-07-01 Shunichi Shiozawa Uso de una secuencia genica promotora para el tratamiento de enfermedades reumaticas.
EP1350514A3 (de) 1993-10-29 2004-07-07 The Brigham And Women's Hospital, Inc. Therapeutische Verwendung von Cis-Element Ködern in vivo
US6399376B1 (en) * 1993-11-05 2002-06-04 Isis Pharmaceuticals, Inc. Modulation of vascular cell adhesive molecule expression through oligonucleotide interactions
ATE357922T1 (de) * 1995-05-12 2007-04-15 Anges Mg Inc Heilung und vorbeugung von durch nf-kappab verursachten erkrankungen
EP1008352A4 (de) * 1997-07-04 2005-03-16 Fujisawa Pharmaceutical Co Gehirnschützender wirkstoff
US20050203612A1 (en) * 2000-12-22 2005-09-15 Avantec Vascular Corporation Devices delivering therapeutic agents and methods regarding the same
DE60225899T2 (de) * 2001-02-20 2009-04-09 AnGes MG Inc., Ibaraki-shi TOPISCHE ANWENDUNG EINES NF-kB DECOYS ZUR BEHANDLUNG ATOPISCHER DERMATITIS
US20050175539A1 (en) * 2001-11-22 2005-08-11 Ryuichi Morishita Compositions inhibiting rejection in organ transplantation and method of using the same
WO2003063911A1 (fr) * 2002-02-01 2003-08-07 Anges Mg, Inc. Compositions pharmaceutiques contenant un leurre et procede d'utilisation
JPWO2003082331A1 (ja) * 2002-03-29 2005-07-28 アンジェスＭｇ株式会社 脳疾患および障害を処置および予防するためのデコイ組成物
CN1306964C (zh) * 2002-05-29 2007-03-28 安琪士摩奇株式会社 治疗和预防炎症性疾病的诱饵组合物
AU2003303521A1 (en) * 2002-12-31 2004-07-29 Genta Incorporated Combination of gallium compounds with nonchemotherapeutic anticancer agents in the treatment of neoplasia
EP1462111A1 (de) * 2003-03-28 2004-09-29 Universiteit Utrecht Holding B.V. Zubereitung zur Induktion von Immuntoleranz
US20040191779A1 (en) * 2003-03-28 2004-09-30 Jie Zhang Statistical analysis of regulatory factor binding sites of differentially expressed genes
WO2005051229A2 (en) * 2003-11-24 2005-06-09 Avantec Vascular Corporation Devices delivering therapeutic agents and methods regarding the same
WO2005056020A2 (en) * 2003-12-02 2005-06-23 Corgentech, Inc. Nf-kb oligonucleotide decoy molecules
US7585848B2 (en) * 2005-01-11 2009-09-08 Rush University Medical Center Methods and compositions for treating, inhibiting and reversing disorders of the intervertebral disc
US20060258604A1 (en) * 2005-05-10 2006-11-16 Warren Strober Compositions and methods for the treatment of inflammatory bowel disease utilizing NF-kappaB decoy polynucleotides

Also Published As

Publication number Publication date
EP1350514A3 (de) 2004-07-07
ES2307293T3 (es) 2008-11-16
US20020128217A1 (en) 2002-09-12
US6821956B2 (en) 2004-11-23
EP0732929A4 (de) 2001-11-14
ATE395065T1 (de) 2008-05-15
WO1995011687A1 (en) 1995-05-04
DE69435100D1 (de) 2008-06-26
US20040229833A1 (en) 2004-11-18
EP0732929B1 (de) 2008-05-14
EP1350514A2 (de) 2003-10-08
EP1340505A3 (de) 2004-07-14
US6774118B1 (en) 2004-08-10
US20030186922A1 (en) 2003-10-02
PT732929E (pt) 2008-08-26
EP1340505A2 (de) 2003-09-03
EP0732929A1 (de) 1996-09-25
US20020052333A1 (en) 2002-05-02

Similar Documents

Publication Publication Date Title
DK0732929T3 (da) Terapeutisk anvendelse af cis-element-afledere in vivo
RU2164944C1 (ru) Способ изменения генетических свойств организма
AU2989300A (en) Controlling protein levels in eucaryotic organisms
DK0563278T3 (da) Regulering af geneekspression med ioniserende stråling
EP1140971A4 (de) Antisens-modulierung von neuartigen anti-apoptotischen bcl-2-artigen proteinen
DK1061940T3 (da) Anvendelse af follistatin til fremstilling af et medikament til behandling af muskelrelaterede lidelser
NO20006078L (no) N-bundete sulfen-amider av N-heterocykliske karboksylsyrer eller karboksylsyre-isostere
DE69804927D1 (de) Vorrichtung zur Behandlung von Tachykardien auf der Basis von ventrikulären Stabilität
HUP9603484A2 (hu) Gyógyászati készítmények és eljárás ingerületátvitel befolyásolására
DK0386734T3 (da) Immunogene regioner på E-7-proteinet af humant papillomavirus type 16
DE69333529D1 (de) Pflanzenvirus-vektor, plasmid, methode der expression fremder gene und methode zur gewinnung obiger genprodukte
DK1011723T3 (da) 88KDA tumorgen vækstfaktor og antagonister
DE60027870D1 (de) Genetische manipulierte herpesviren zur behandlung von tumoren
DE69635349D1 (de) Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung
NO924309L (no) Sammensetninger og fremgangsmaater for modulering av rna-aktiviteter gjennom modifikasjon av 5' cap-strukturen til rna
EA200001130A1 (ru) Промотор гена вмп-7 человека и способ анализа с его использованием вещества, связанного с костной тканью
ATE320270T1 (de) Zusammensetzungen und methoden zur zielgerichteten abgabe von biologisch aktivenfaktoren
NO308396B1 (no) FremgangsmÕte ved fremstilling av substanser av polypeptidnatur
Nelwan Treat oculocutaneous albinism with gene therapy
DE3786586D1 (de) Genexpressionssystem.
ATE148109T1 (de) Hiv-proteaseinhibitoren und ihre verwendung zur behandlung von aids
DE19681032D2 (de) Gentherapeutisches Nukleinsäurekonstrukt, seine Herstellung und Verwendung zur Behandlung von Herzerkrankungen
DE69836315D1 (de) Verwendung von TCF-II zur Behandlung von durch Krebs verursachtem Gewichtsverlust, Anaemie und TNF-Erhöhung
Idrissou et al. Exciting history of Tip60 and its companions in carcinogenesis across the heterochromatin landscapes
EP1887083B1 (de) Verwendung der 5'UTR des D.melanogaster ZAM Retrotransposons als "Isolator" um eine hohe Transgen-Expression zu garantieren